San Francisco, California — Hims & Hers announced on Saturday that it will cease offering a compounded version of Novo Nordisk’s weight-loss medication through its telehealth platform. This decision follows recent calls from health authorities for an investigation into potential violations of federal regulations related to the drug’s marketing and distribution.

The compounded medication was introduced earlier in the week at a price of $49 per month, significantly lower than Novo Nordisk’s original pill, which retails between $149 and $299 monthly. The introduction of Hims & Hers’ product swiftly drew criticism from Novo Nordisk, which had only recently launched its own oral version of the injectable drug Wegovy.

The legality of compounding a mass-market version of a drug typically hinges on whether the original product is in short supply. At this time, Wegovy is not listed as a shortage medication, raising questions regarding Hims & Hers’ practices.

In response to the compounded medication, the Food and Drug Administration (FDA) signaled its intention to take significant action against companies that market unapproved versions of medications classified as GLP-1 drugs. Additionally, the Department of Health and Human Services has requested a formal investigation by the Department of Justice into Hims & Hers’ recent actions.

The move to investigate Hims & Hers underscores a broader concern over compounded drugs and their impact on patient safety and the pharmaceutical marketplace. Critics argue that such products could undermine the integrity of approved medicines and create confusion among consumers.

Hims & Hers has yet to comment on the implications of the investigation or what steps it will take moving forward. The company’s abrupt decision to halt sales may reflect both heightened scrutiny and a commitment to comply with regulatory standards.

As the telehealth industry continues to evolve, the case of Hims & Hers serves as a cautionary tale about the complexities and risks associated with compounded medications. Experts emphasize the importance of maintaining robust oversight to ensure that patient safety remains a top priority within this rapidly growing sector.